Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSaglik Bilimleri Universitesi
About this trial
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.
Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients between the ages of 18 -75
Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy
Disqualifiers
Patients over 18 years old and under 75 years old
Patients with malignancy detected in another focus with preoperative Bethesda III FNAC
Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy
Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing
Trial population
Patients between the ages of 18 -75
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
120 Participants
are grouped into 1 trial groupGroup A: 2/Group B (Benign), Group M (Malign)
Trial outcomes
Primary outcomes
1
Mean Platelet Volume (MPV) (fL)
Mean Platelet Volume (MPV) (fL) values will be taken and recorded in the preoperative hemogram parameters of all patients.
Time frame
1 week2
Neutrophil/lenfosit Ratio (NLR)(103/µL)
Neutrophil/lymphocyte ratio (NLR) will be calculated by taking the Neutrophil (103/µL) and Lymphocyte (103/µL) values in the preoperative hemogram parameters of all patients.
Time frame
1 week3
Platelet/Lenfosit Ratio (PLR)(103/µL)
Platelet/lymphocyte ratio (PLR) will be calculated by taking the Platelet (103/µL) and Lymphocyte (103/µL) values in the preoperative hemogram parameters of all patients.
Time frame
1 week4
Lenfosit/Monosit Ratio (LMR)(103/µL)
Lymphocyte/Monocyte Ratio (LMR) will be calculated by taking the Lymphocyte (103/µL) and Monocyte (103/µL) values in the preoperative hemogram parameters of all patients.
Time frame
1 weekSecondary outcomes
1
BRAF molecular test
Pathological molecular test (25 patients)
Time frame
1 weekSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov